Home
overview

The SMi Group is delighted to announce its 20th Annual Pain Therapeutics conference held in London on the 11th and 12th May 2020.

The Global Pain Therapeutics Market was valued at $11.26 Million in 2018 and is projected to reach $15.87 Million by 2026, growing at a CAGR of 4.40 % from 2019 to 2026. Improving pain management continues to be a priory as pain-derived disabilities such as osteoarthritis, back pain, migraines and cancer are leading cause of disability worldwide. Yet, pain treatment remains the biggest clinical burden of the age as a result of lack of efficacy, increasing side effects and the opioid crisis that is now entering Europe following its epidemic in the USA.

The 20th Annual Conference will overview the current state of pain treatment highlighting clinical success to date as well as evaluating the potential of drug candidates in the pipelines.

Join Europe's leading Pain Therapeutics Conference which will explore the cutting-edge research of novel therapeutics in the pipeline of leading pharmaceutical companies and research institutions. Discuss solutions for the challenges of understanding pain as a heterogenous disease and the diverse treatment approaches it requires.

• Network with leading pharmaceutical companies and academic researchers of the pain community including GSK, Centrexion, Grunenthal Group, Mundipharma Research Limited, UCL, Janssen, University of Edinburgh and many more!

• Rethink pain research by exploring novel biomarkers, sex differences in nociception, pain clinical trial design and novel targets

• Learn about the struggles of opioid-based treatments and explore the current stages of clinical research with non-opioid targets such as; cannabinoid receptor 2, nociception/orphanin FQ peptide (NOP) receptor, ENKephalinase and NGF receptors

• Improve your understanding of neuro-immune interactions and their role in pain pathology, a promising new angle of pain research
 

Chief Executive Officers, Chief Scientific Officers, Chief Medical Officers, Managing Directors, CEO, Head of Departments, Principal Research Scientists, Clinical Lead, Clinical Operations in the following fields:

  • Pain and Migraine
  • Pain Innovation R&D
  • Neuroscience
  • CNS
  • Neuropathic Pain
  • Analgesic clinical development
  • Anesthesia and Pain Management
  • CNS clinical trials
  • Translational science
  • Drug development
  • Discovery Medicine
  • Exploratory development
  • Clinical and pharmaceutical operations
  • Medical Affairs

Adynxx Inc.; Alterion Consulting; Asahi Kasei Pharma; Asahi Kasei Pharma Corporation; AstraZeneca; AstraZeneca R&D Biopharmaceuticals; Bayer AG; BRAINCURES LTD; Centre for Human Drug Research; Centrexion Therapeutics Corp; Clexio Biosciences; Domain Therapeutics ; Eli Lilly and Company; Ensysce Biosciences Inc.; Grunenthal; Grünenthal GmbH; Grunenthal Group; Grunenthal Ltd; GSK; Janssen Pharmaceutica N.V.; Levicept; Lotus Clinical Research, LLC; MD Biosciences; Medherant Limited; Metys Pharmaceuticals Ltd; Pfizer Ltd; Pharmaleads; Reckitt Benckiser; Tools4patient; Travecta Therapeutics; UMR 1107 INSERM/UCA NEURO-DOL; Vertex Pharmaceuticals; ViroMed ;

Conference programme

8:30 Registration & Coffee

9:00 Chairs' Opening Remarks

Kerrie Brady

Kerrie Brady, Chief Business Officer, Centrexion Therapeutics Corp
View Bio

Michael Scherz

Michael Scherz, Founder & CEO, Metys Pharmaceuticals Ltd
View Bio

9:10 Facilitating Pain Research via Biomarker Discovery

Richard Malamut

Richard Malamut, Chief Medical Officer and SVP R&D, Collegium Pharma
View Bio

•Evaluating the role of biomarkers in pain research
•Identifying biomarkers – where are we now?
•Establishing biomarkers in patient populations
•Highlighting the importance of biomarker discovery and its contribution to early stage studies on pain

9:50 Bridging the translational gap in analgesic drug development

Zahid Ali

Zahid Ali, Head Clinical Pharmacology Translational Sciences, Mundipharma research Ltd
View Bio

•What have we learnt from over 20 years of concerted analgesic drug development?
•The integration of clinical, non-clinical and disease area knowledge for more effective decision making
•The impact of new technologies on translational approaches in analgesic drug development
•One size does not fit all- developing more targeted and effective analgesics

10:30 Morning Coffee

11:00 Neurotrophins in pain models

Cristina Cosi

Cristina Cosi, Senior Scientist Pharmacology, CNS Innovation Unit, Pierre Fabre Research Institute
View Bio

•Pain models for pre-clinical research
•Focus on BDNF, NGF, TrkB, TrkA systems
•Biomarkers, target validation and engagement
•Considering translatability of pain across species

11:40 Sex Differences in Pain Mechanisms

Carole Torsney

Carole Torsney, Senior Lecturer, University of Edinburgh
View Bio

•Highlight evidence for sex differences in neuro-immune interactions
•Highlight evidence for sex differences in PNS and CNS plasticity
•Discuss sex differences in the temporal relay of pain signals by nociceptors
•Address the need for preclinical research on both sexes to improve translation

12:20 Networking Lunch

13:20 Pain clinical trials - myths and momentum

Kerrie Brady

Kerrie Brady, Chief Business Officer, Centrexion Therapeutics Corp
View Bio

•Examining pain clinical trial myths
•Raising patient awareness to improve clinical trials
•Consideration of new clinical trial design approaches

14:00 Panel Discussion: Novel drug targets on the horizon

•Discussing the diversity of targets that have been explored for the treatment of neuropathic pain
•Evaluating the current situation and status of targets in clinic
•What are the new targets on the horizon that should be fully explored?
•Starting with a target ending with a drug – challenges encountered

Richard Malamut

Richard Malamut, Chief Medical Officer and SVP R&D, Collegium Pharma
View Bio

Sandrine Geranton

Sandrine Geranton, Associate Professor, UCL Institute of Ophthalmology
View Bio

Jennifer Laird

Jennifer Laird, Senior Director, Search & Evaluation at Eli Lilly, Eli Lilly And Company
View Bio

Zahid Ali

Zahid Ali, Head Clinical Pharmacology Translational Sciences, Mundipharma research Ltd
View Bio

14:40 Selecting targets for a novel pain therapy: Expanding the druggable space

Jennifer Laird

Jennifer Laird, Senior Director, Search & Evaluation at Eli Lilly, Eli Lilly And Company
View Bio

•Translatability of preclinical evidence is debated in the pain field, but are there exceptions that prove (or disprove) the rule?
•Alternatively, can we take an opportunistic approach and focus on targets with clinical evidence provided by serendipity?
•This presentation will address those questions and also discuss how novel modalities like oligonucleotides or gene therapy can change the types of targets we focus our efforts on
 

15:20 Afternoon Tea

15:50 FKBP51 and the stress axis: novel targets for the control of chronic pain

Sandrine Geranton

Sandrine Geranton, Associate Professor, UCL Institute of Ophthalmology
View Bio

•Stress and chronic pain are known to exacerbate each
other but the underlying mechanisms remain elusive
•FKBP51 is a well-known regulator of the stress axis and its inhibition improves anxiety-like behaviour in mouse models
•We have shown that FKBP51 is a crucial driver of persistent pain states
•Targeting the stress axis overall is likely to reduce the pain experience

16:30 Evaluation of the Selective Cannabinoid 2 Receptor Agonist CNTX-6016 for the Treatment of Neurophatic pain

James Campbell

James Campbell, Chief Scientific Officer , Centrexion Therapeutics Corp

•Introducing CB2 receptors as targets and their implication in pain
Presenting recent result from clinical trials of CNTX-6016
•Implications for treatment of chronic neuropathic pain, such as diabetic neuropathic pain and chemotherapy induced neuropathy

17:10 What can we Learn from the Opioid Crisis?

Theo Meert

Theo Meert, Head of R&D Global Government Grant Office, Janssen Pharmaceutica N.V.
View Bio

•Addressing the global misuse of opioids and evaluating
new treatment options
•Raising public awareness and taking the society and sociological consequences into account
•Highlighting what action needs to be taken to restrict
opioid overuse
•Discussing lessons learnt and how can these be applied
to avoid a potential “ketamine crisis”?

8:30 Registration & Coffee

9:00 Chairs' Opening Remarks

Kerrie Brady

Kerrie Brady, Chief Business Officer, Centrexion Therapeutics Corp
View Bio

Michael Scherz

Michael Scherz, Founder & CEO, Metys Pharmaceuticals Ltd
View Bio

9:10 The impact of chronic pain – the patient’s perspective

Joop van Griensven

Joop van Griensven, President , Pain Alliance Europe (PAE)
View Bio

•Understanding the effects of chronic pain on the quality of life and on society
•Observing health aspects of chronic pain
•Promoting awareness and helping patient cope with chronic pain

9:50 Revolutionising pain R&D by developing Precision Analgesics

Mark  J Field

Mark J Field, Owner/Founder, Analgesic Innovation

•Overviewing the impact of pain and its huge global burden with up to 1 in 4
•Discussing the pain therapeutics- an area with the LOWEST R&D success rates
•Learning what factors are hindering analgesic development
•Developing precision analgesics can radically improve probability of success

10:30 Morning Coffee

11:00 The role of Neuro-Immune Interactions in Chronic Pain

Edward Emery

Edward Emery, Investigator, GSK
View Bio

•Introducing the concept of interacting neurons and immune cells in the pathophysiology of pain
•Exploring the contributions of the immune system to chronic pain
•Understanding the role of the immune system in pain facilitation
•Overviewing potential strategies for targeting the immune system to treat pain

11:40 Emphasising Disease Understanding to deliver effective pain treatments. Exploring NOP receptor pharmacology as an exciting opportunity to treat neuronal hypersensitivity driven pain disorders

Paul Ratcliffe

Paul Ratcliffe, Vice President, Setup Innovation Hubs , Grunenthal Group
View Bio

•Grunenthal’s approach to tackle the underlying pathophysiologies of pain

•Targeting the nociception/orphanin FQ peptide (NOP) receptor; a journey navigating between the pre-clinic and clinical environment

12:20 Networking Lunch

13:20 Novel botulinum-based constructs for the long-term control of persistent pain states in mice

Stephen Hunt

Stephen Hunt, Professor, UCL
View Bio

•The evidence for opiate control of chronic pain states is poor
•This is related to the development of tolerance, increased pain sensitivity and therefore escalating dose of opiate drug that can lead to addiction.
•A novel conjugation of dermorphin to the silencing domain of botulinum toxin, that is safe to produce under laboratory conditions, results in long term amelioration of persistent pain states in mice following one intrathecal injection.
•The analgesia lasts for over three months without killing neurons or obvious toxic events

14:00 Fremanezumab Clinical Trials: Results in a Broad Range of Migraine Patients, Including Those with Difficult-to Treat Migraine

Joshua M. Cohen

Joshua M. Cohen, Global Medical Lead for Migraine & Headache, Teva Pharmaceuticals
View Bio

  • Overall Trial Results in Episodic and Chronic Migraine with Quarterly and Monthly Dosing
  • Patients with Comorbid Depression
  • Patients with Medication Overuse
  • Patients with Prior Treatment Failures
  • 14:40 Afternoon Tea

    15:10 Limitations of Current Migraine Treatment Options: the Patients’ Perspective

    Domenico Merante

    Domenico Merante, VP Clinical Development, Independent

    •Overviewing the current migraine treatment landscape with special focus on the patient
    •How do patients respond to available treatment?
    •Considering aspects of tolerability and side effects
    •Examining efficacy limitations of current treatments

    15:50 Recent Progress of PL37 – a Dual ENKephalinase Inhibitor for migraine treatment

    Tanja Ouimet

    Tanja Ouimet, Head of Clinical Operations, Pharmaleads
    View Bio

    •Introducing DENKI and PL37 MoA
    •Presenting recent preclinical pharmacology results on the potential of PL37 in migraine treatment
    •Assessing the potential of PL37 and future studies required

    17:00 Chairman’s Closing Remarks and Close of Day Two

    +

    FEATURED SPEAKERS

    Carole Torsney

    Carole Torsney

    Senior Lecturer, University of Edinburgh
    Cristina Cosi

    Cristina Cosi

    Senior Scientist Pharmacology, CNS Innovation Unit, Pierre Fabre Research Institute
    Domenico Merante

    Domenico Merante

    VP Clinical Development, Independent
    Edward Emery

    Edward Emery

    Investigator, GSK
    James Campbell

    James Campbell

    Chief Scientific Officer , Centrexion Therapeutics Corp
    Jennifer Laird

    Jennifer Laird

    Senior Director, Search & Evaluation at Eli Lilly, Eli Lilly And Company
    Joop van Griensven

    Joop van Griensven

    President , Pain Alliance Europe (PAE)
    Kerrie Brady

    Kerrie Brady

    Chief Business Officer, Centrexion Therapeutics Corp
    Mark  J Field

    Mark J Field

    Owner/Founder, Analgesic Innovation
    Paul Ratcliffe

    Paul Ratcliffe

    Vice President, Setup Innovation Hubs , Grunenthal Group
    Richard Malamut

    Richard Malamut

    Chief Medical Officer and SVP R&D, Collegium Pharma
    Sandrine Geranton

    Sandrine Geranton

    Associate Professor, UCL Institute of Ophthalmology
    Stephen Hunt

    Stephen Hunt

    Professor, UCL
    Tanja Ouimet

    Tanja Ouimet

    Head of Clinical Operations, Pharmaleads
    Theo Meert

    Theo Meert

    Head of R&D Global Government Grant Office, Janssen Pharmaceutica N.V.
    Zahid Ali

    Zahid Ali

    Head Clinical Pharmacology Translational Sciences, Mundipharma research Ltd

    Carole Torsney

    Senior Lecturer, University of Edinburgh
    Carole Torsney

    Carole Torsney is a Senior Lecturer in the Centre for Discovery Brain Sciences at the University of Edinburgh. Carole Torsney received her PhD from University College London as part of the Wellcome Trust 4 year PhD programme in Neuroscience with Professor Maria Fitzgerald. Following postdoctoral training at Columbia University, New York with Professor Amy MacDermott she was then awarded a Caledonian Research Foundation Fellowship, then Senior Academic Fellowship followed by a Lectureship at the University of Edinburgh. She studies pain pathophysiology primarily using electrophysiological approaches and is a member of the Edinburgh Translational Pain Research Group.

    Cristina Cosi

    Senior Scientist Pharmacology, CNS Innovation Unit, Pierre Fabre Research Institute
    Cristina Cosi

    Biologist and pharmacologist , biochemist by training , with a Master in Science from the University of Florence , and a PhD in Pharmacology from the University of Toulouse, 1997, Cristina Cosi has an extensive working experience in the Neuroscience research field, mostly in industry at Pierre Fabre, France, but also in academic environments, in Italy , University of Florence and Verona, and US, NIH. She has focused her career on the understanding of neurodegenerative processes and mechanisms of neuronal plasticity in order to find medications that might be beneficial against neurodegenerative and neurodevelopmental diseases and pain.

    Domenico Merante

    VP Clinical Development, Independent
    Domenico Merante

    Edward Emery

    Investigator, GSK
    Edward Emery

    Ed started his career in pain research in the lab of Prof. Peter McNaughton at the University of Cambridge in 2008, investigating the role of HCN2 ion channels in chronic pain. Ed went on to complete postdoctoral positions with Prof. Fiona Gribble at the Institute of Metabolic Science, in Cambridge and with Prof. John Wood at University College London, where his work was focussed on understanding the role of voltage-gated sodium channels in nociception, as well as developing imaging techniques to study sensory neuron physiology, in vivo. In April 2019, Ed moved to GSK to help suport their pain research strategy.

    James Campbell

    Chief Scientific Officer , Centrexion Therapeutics Corp
    James Campbell

    Jennifer Laird

    Senior Director, Search & Evaluation at Eli Lilly, Eli Lilly And Company
    Jennifer Laird

    Jennifer Laird, Ph.D., D.Sc. is Vice-President, Search & Evaluation Pain & Neurodegeneration at Eli Lilly and Company, based at Lilly’s European Headquarters, London, UK. Her role, along with her team, is to complement Lilly’s internal R&D efforts by in-licensing or acquiring novel therapeutics and technologies for the Lilly portfolio, and to advance molecules through drug discovery and development in collaboration with external partners globally. Prior to joining Lilly in 2012, Dr. Laird held leadership roles in Translational Science, Project Management and Pharmacology at AstraZeneca, in academia and Merck, primarily focused on the discovery and development of novel analgesics. Dr. Laird served as an Editorial Board member of Pain, Neuropharmacology and European Journal of Pain and held an honorary appointment as Professor of Pharmacology at McGill University, Canada. She received doctorates from the University of Bristol, UK and University of Alicante, Spain, and post-doctoral training at NIH, USA.

    Joop van Griensven

    President , Pain Alliance Europe (PAE)
    Joop van Griensven

    Joop was born in Tilburg, in the Netherlands, is married, has a son, a daughter and a grandchild.

    Because of physical problems (fibromyalgia) Joop lost his job at the age of 35. Since 2008 he has been involved in the European Network of Fibromyalgia Associations, as treasurer. Since 2011 he is the President of Pain Alliance Europe (PAE), a European umbrella alliance of national associations involved with chronic pain.

    He is member of the patient advisory board of the Dutch Medicines Evaluation Board (CBG/MEB) and act as a patient expert on pain and fibromyalgia for the European Medicine Agency (EMA).


     

    Joshua M. Cohen

    Global Medical Lead for Migraine & Headache, Teva Pharmaceuticals
    Joshua M. Cohen

    Joshua M. Cohen, MD, MPH, FAHS is Global Medical Lead for Migraine & Headache at Teva Pharmaceuticals. He completed Board certification in Neurology and Headache Medicine. He was chosen as a Super Doctors® 2013 and 2014 New York Rising Stars™ and was selected as a Castle Connolly America’s Top Doctors™ in 2015. Dr. Cohen completed undergraduate training at Harvard University, medical school at the New York University School of Medicine, and neurology residency at Columbia University's Neurological Institute. At the Columbia Mailman School of Public Health, he received his Masters of Public Health. He completed headache fellowship at The Headache Institute.
     

    Kerrie Brady

    Chief Business Officer, Centrexion Therapeutics Corp
    Kerrie Brady

    Kerrie Brady is a founder and chief business officer of Centrexion Therapeutics. Kerrie’s career includes 30 years of experience as an international pharmaceutical executive working in both big pharma and biotech companies. Prior to joining Centrexion, Kerrie was the chief operations officer for Vallinex Inc., a company she founded as a spin out from Arcion Therapeutics, Inc., a biotech company developing topical products for the treatment of neuropathic pain. Kerrie was also the co-founder and chief operations officer for Arcion Therapeutics Inc. Previously, she was the founder, president and chief executive officer of Traxion Therapeutics, Inc., a biotech company focused on the development of new drugs to treat intractable pain. Prior to starting on the entrepreneurial path Kerrie’s experience spanned business development (KMG Japan, Entremed, Intracel), business operations (CMC for Biopharmaceutical Research), marketing and regulatory affairs (Rhone Poulenc) Kerrie holds a BPharm from Victorian College of Pharmacy, an MBA from the University of Melbourne and an M.S. in biopharmaceuticals from the University of New South Wales. In 2016, Kerrie was named to the PharmaVOICE100 Most Inspiring People for her contributions to the life-sciences industry.

    Mark J Field

    Owner/Founder, Analgesic Innovation
    Mark  J Field

    Michael Scherz

    Founder & CEO, Metys Pharmaceuticals Ltd
    Michael Scherz

    Michael Scherz manages drug development and drug discovery activities at Metys Pharmaceuticals, and is spearheading the company’s search for Series A investors. He is responsible for managing the corporate budget, and
    for the selection of suitable consultants for Metys’ drug development and drug discovery activities. He is
    responsible for Metys’ development plans for MP-101, a newly-patented orally-active Phase II-ready small molecule intended for the treatment and prevention of neuropathic pain, in a first clinical trial for the prevention of chemotherapy-induced symptoms of peripheral neuropathy. Since creating Metys Pharmaceuticals, Scherz has worked to share Metys’ vision and strategy with its investors and consultants.
    Michael Scherz graduated in 1989 from the University of Oregon with a PhD in synthetic and medicinal
    chemistry. Previously, he served as vice president and life cycle leader at Actelion Pharmaceuticals, where he was responsible for the multi-functional development teams entrusted with the Phase I to Phase III clinical development of several novel therapeutic agents. His focus on innovation, team performance, and clear communication, led to the discovery of novel candidate therapeutic agents: urotensin-II antagonists, sphingosine-1-phosphate agonists, and novel calcium channel blockers; and significant advancements of the Phase I to pre-Phase III clinical projects he led. Prior to Actelion, Scherz was section head of cardiac research at Procter & Gamble Pharmaceuticals in Cincinnati, Ohio, USA; and post-doc at Hoffman-La Roche AG in Basel, Switzerland.
     

    Paul Ratcliffe

    Vice President, Setup Innovation Hubs , Grunenthal Group
    Paul Ratcliffe

    A scientist and entrepreneurial leader with extensive expertise in drug discovery and early development. Recognised as an innovative and visionary mentor with strong motivational and change management skills, able to nurture teams to ensure successful project delivery. A track record of leading international projects in both large and mid-sized Pharma and adept at developing global collaborative networks and partnerships with Biotechs, CROs and Academic institutes. A member of the R&D leadership Team he is currently responsible for the implementation of Grünenthal’s Innovation Hub strategy within Europe and China, tasked with driving research and early clinical projects to Proof of Concept.
     

    Richard Malamut

    Chief Medical Officer and SVP R&D, Collegium Pharma
    Richard Malamut

    Dr Malamut is currently Chief Medical Officer and Executive Vice President at Collegium Pharmaceuticals which is committed to be the leader in responsible pain management. He has also served as Chief Medical Officer for Braeburn Pharmaceuticals, Inc. where he was responsible for the company’s medical affairs, non-clinical and clinical development, clinical operations, research and development quality assurance, and pharmacovigilance functions. Prior to that, Dr. Malamut had similar responsibilities as Chief Medical Officer at Avanir Pharmaceuticals and was Senior Vice President of Global Clinical Development at Teva Pharmaceutical Industries Ltd where he was responsible for Pain, Neuropsychiatry, Oncology, and New Therapeutic Entities. His experience also includes roles of increasing responsibility focusing on early clinical development and translational medicine in Neurology, Psychiatry and Analgesia at Bristol-Myers Squibb and AstraZeneca.

    Dr. Malamut earned his medical degree from Hahnemann University in Philadelphia and completed both a residency in Neurology and a fellowship in Neuromuscular disease. He worked as a board-certified academic and clinical neurologist for 17 years and has more than 50 publications in the fields of pain medicine, neuromuscular disease, autonomic disease, and neurodegenerative disease.
     

    Sandrine Geranton

    Associate Professor, UCL Institute of Ophthalmology
    Sandrine Geranton

    Sandrine Géranton is Associate Professor in molecular neuroscience in the department of Cell and Developmental Biology at University College London. Sandrine studied organic chemistry and biochemistry at the “Ecole Nationale Supérieure de Chimie de Montpellier” in France. After an MSc in biotechnology, she joined UCL where she obtained a PhD in Pharmacology. She went on learning about pain mechanisms as a post-doctoral researcher with the London Pain Consortium at UCL, where she is now Associate Professor. Sandrine has always been keen on applying her multidisciplinary background to further her understanding of the molecular biology of chronic pain and she has been at the forefront of the investigation of the role of epigenetic mechanisms in this context.

    Stephen Hunt

    Professor, UCL
    Stephen Hunt

    Professor Stephen Hunt received his doctorate in Neuroscience from University College London (UCL). From 1980 he was a scientific staff member at the Lab of Molecular Biology in Cambridge but moved back to UCL in 1998 as Professor of Molecular Neuroscience. His research has been concentrated on the relationship between molecules and behaviour particularly around the neurobiology of pain, depression and addiction. Most recently he has been working with Professor Bazbek Davletov and Dr Maria Maiaru leveraging the neurotoxic properties of the botulinum toxin to specifically silence key pain-processing neurons. He was elected a fellow of the Academy of Medical Sciences in 2001.

    Tanja Ouimet

    Head of Clinical Operations, Pharmaleads
    Tanja Ouimet

    Tanja holds a PhD in Neurosciences from the University of Montréal. She then moved to Paris to pursue her research on metalloproteases as drug targets in academia before joining Pharmaleads in 2006 as Head of Biochemistry, characterizing metalloprotease and inhibitor activity in vitro and in vivo, through the design of specific assays. Her work was essential in selecting Pharmaleads’ drug candidates, Dual Enkephalinase Inhibitors (DENKI) for preclinical and clinical development in the treatment of severe pain.
    In 2014, Tanja was appointed Head of Clinical Operations overseeing all operational aspects of the DENKIs clinical trials. She was named Director of Clinical Development in 2017.
     

    Theo Meert

    Head of R&D Global Government Grant Office, Janssen Pharmaceutica N.V.
    Theo Meert

    Prof Theo F. Meert is head of the R&D Global Government Grant office (G3O) of J&J. He is also a professor and scientific advisor/researcher at different universities: Leuven, Antwerp, Hasselt and Ghent.
    During his career at J&J that started in 1981, Dr. Meert has been appointed to multiple international global functions. Within his various functions, he guided different multidisciplinary research teams, some with full development drugs, in the field of CNS, including pain.
    Dr. Meert’s scientific expertise is reflected in multiple patents (>15), publications (> 243), congress communications (> 200) and invited lectures (>190). Dr. Meert obtained a Ph.D. in psychopharmacology and a Ph.D. in Medicine/Anesthesiology
     

    Zahid Ali

    Head Clinical Pharmacology Translational Sciences, Mundipharma research Ltd
    Zahid Ali

    At Mundipharma research Zahid is part of the team that in-licenses and develops assets for pain and non- pain indications. During his industry career he has focused on translational medicine - initially at MSD followed by GSK and Pfizer where he has led multiple projects including pain related Nav1.7, Nav1.8 and P2X7. He has also extensively represented industry in precompetitive consortia including IMI Europain 1. Prior to his current role, Zahid was the CSO for a London based biotech Calchan Ltd which included a Cav2.2 blocker and ASK1 inhibitor in the portfolio which were being developed for pain and fibrosis.

    VENUE

    Copthorne Tara Hotel

    Scarsdale Place, Kensington, London, United Kingdom

    The Copthorne Tara Hotel London Kensington is an elegant contemporary four-star hotel in prestigious Kensington, located just a two minutes walk from High Street Kensington underground station, making exploring easy. The hotel offers well-appointed and comfortable guest rooms combining Standard, Superior and Club accommodation. Club rooms offer iconic views over the city and include Club Lounge access for complimentary breakfast and refreshments. Guests can sample the authentic Singaporean, Malaysian and Chinese cuisine at Bugis Street, traditional pub fare at the Brasserie Restaurant & Bar or relax with a delicious drink at West8 Cocktail Lounge & Bar.

    The Copthorne Tara Hotel boasts 745 square meters of flexible meeting space, consisting of the Shannon Suite and the Liffey Suite, ideal for hosting conferences, weddings and social events. Facilities include access to the business centre 24 hours a day, fully equipped fitness room, gift shop, theatre desk and Bureau de Change. With ample onsite parking outside the London congestion charge zone and excellent transport links via Heathrow Airport, the hotel is the perfect location for business or leisure stays. The hotel is within close proximity to the shops of High Street Kensington, Knightsbridge and Westfield London, Olympia Conference Centre, Royal Albert Hall, Kensington Palace and Hyde Park.

     

    A number of our clients have been approached by third party organisations offering to book hotel rooms. We would advise that you do not book through them as they are not representing the SMi Group. SMi Group books all hotel rooms directly. If you are approached by a third party organisation then please contact us before making any bookings. If you have already booked a hotel room using a third party organisation, we would highly recommend contacting the hotel you were booked into to ensure a booking has been made for you. We would also advise you to please check the terms and conditions of the booking carefully.
    HOTEL BOOKING FORM

    Speaker Interview with Stephen Hunt

    Download

    Co-Chair Invite Letter

    Download

    2020 Conference Speakers

    Download

    Pain Therapeutics 2020 Brochure

    Download

    Two Day Programme 2020

    Download

    Past Attendees

    Download

    Pain Therapeutics Conference 2019 - Janssen

    Download

    Pain Therapeutics Conference 2019 - CHDR

    Download

    Pain Therapeutics Conference 2019 - Ensysce Biosciences

    Download

    Pain Therapeutics Conference 2019 - Pfizer

    Download

    Pain Therapeutics Conference 2019 - Lotus

    Download

    Pain Therapeutics Conference 2019 - Centrexion

    Download

    SAVE TO


    Outlook Calendar  OUTLOOK CALENDAR
    Google Calendar  GOOGLE CALENDAR
    ICal Calendar  ICAL CALENDAR
    Yahoo! Calendar  YAHOO! CALENDAR

    Copthorne Tara Hotel

    Scarsdale Place
    Kensington
    London W8 5SR
    United Kingdom

    Copthorne Tara Hotel

    The Copthorne Tara Hotel London Kensington is an elegant contemporary four-star hotel in prestigious Kensington, located just a two minutes walk from High Street Kensington underground station, making exploring easy. The hotel offers well-appointed and comfortable guest rooms combining Standard, Superior and Club accommodation. Club rooms offer iconic views over the city and include Club Lounge access for complimentary breakfast and refreshments. Guests can sample the authentic Singaporean, Malaysian and Chinese cuisine at Bugis Street, traditional pub fare at the Brasserie Restaurant & Bar or relax with a delicious drink at West8 Cocktail Lounge & Bar.

    The Copthorne Tara Hotel boasts 745 square meters of flexible meeting space, consisting of the Shannon Suite and the Liffey Suite, ideal for hosting conferences, weddings and social events. Facilities include access to the business centre 24 hours a day, fully equipped fitness room, gift shop, theatre desk and Bureau de Change. With ample onsite parking outside the London congestion charge zone and excellent transport links via Heathrow Airport, the hotel is the perfect location for business or leisure stays. The hotel is within close proximity to the shops of High Street Kensington, Knightsbridge and Westfield London, Olympia Conference Centre, Royal Albert Hall, Kensington Palace and Hyde Park.

     

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.

    Thank you for visiting our event

    If you would like to receive further information about our events, please fill out the information below.

    By ticking above you are consenting to receive information by email from SMi.
    Full details of our privacy policy can be found here https://www.smi-online.co.uk/privacy-legals/privacy-policy/.
    Should you wish to update your contact preferences at any time you can contact us at data@smi-online.co.uk.
    Should you wish to be removed from any future mailing lists please click on the following link http://www.smi-online.co.uk/opt-out